Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S, Gesierich A, Thiem A, Hufnagel A, Jessen C, Kneitz H, Regensburger M, Schmidt C, Zirkenbach V, Bischler T, Schilling B, Siedel C, Goebeler ME, Houben R, Schrama D, Gehrig A, Rost S, Maurus K, Bargou R, Rosenwald A, Schartl M, Goebeler M, Meierjohann S. Appenzeller S, et al. Among authors: schilling b. Cancer. 2019 Feb 15;125(4):586-600. doi: 10.1002/cncr.31843. Epub 2018 Dec 18. Cancer. 2019. PMID: 30561760 Free article.
miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1.
Krebs M, Behrmann C, Kalogirou C, Sokolakis I, Kneitz S, Kruithof-de Julio M, Zoni E, Rech A, Schilling B, Kübler H, Spahn M, Kneitz B. Krebs M, et al. Among authors: schilling b. Biomed Res Int. 2019 Nov 14;2019:6392748. doi: 10.1155/2019/6392748. eCollection 2019. Biomed Res Int. 2019. PMID: 31828111 Free PMC article.
The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression.
Jessen C, Kreß JKC, Baluapuri A, Hufnagel A, Schmitz W, Kneitz S, Roth S, Marquardt A, Appenzeller S, Ade CP, Glutsch V, Wobser M, Friedmann-Angeli JP, Mosteo L, Goding CR, Schilling B, Geissinger E, Wolf E, Meierjohann S. Jessen C, et al. Among authors: schilling b. Oncogene. 2020 Oct;39(44):6841-6855. doi: 10.1038/s41388-020-01477-8. Epub 2020 Sep 25. Oncogene. 2020. PMID: 32978520 Free PMC article.
Correction: The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression.
Jessen C, Kreß JKC, Baluapuri A, Hufnagel A, Schmitz W, Kneitz S, Roth S, Marquardt A, Appenzeller S, Ade CP, Glutsch V, Wobser M, Friedmann-Angeli JP, Mosteo L, Goding CR, Schilling B, Geissinger E, Wolf E, Meierjohann S. Jessen C, et al. Among authors: schilling b. Oncogene. 2021 Feb;40(7):1391. doi: 10.1038/s41388-020-01535-1. Oncogene. 2021. PMID: 33262465 Free PMC article. No abstract available.
Subgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries.
Marquardt A, Solimando AG, Kerscher A, Bittrich M, Kalogirou C, Kübler H, Rosenwald A, Bargou R, Kollmannsberger P, Schilling B, Meierjohann S, Krebs M. Marquardt A, et al. Among authors: schilling b. Front Oncol. 2021 Mar 15;11:621278. doi: 10.3389/fonc.2021.621278. eCollection 2021. Front Oncol. 2021. PMID: 33791209 Free PMC article.
Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio.
Zimmermann S, Aghai F, Schilling B, Kraus S, Grigoleit GU, Kalogirou C, Goebeler ME, Jung P, Pelzer T, Klinker H, Isberner N, Scherf-Clavel O. Zimmermann S, et al. Among authors: schilling b. J Pharm Biomed Anal. 2022 Mar 20;211:114623. doi: 10.1016/j.jpba.2022.114623. Epub 2022 Jan 29. J Pharm Biomed Anal. 2022. PMID: 35121279
Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors-A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures.
Marquardt A, Hartrampf P, Kollmannsberger P, Solimando AG, Meierjohann S, Kübler H, Bargou R, Schilling B, Serfling SE, Buck A, Werner RA, Lapa C, Krebs M. Marquardt A, et al. Among authors: schilling b. Cancers (Basel). 2023 Jan 6;15(2):392. doi: 10.3390/cancers15020392. Cancers (Basel). 2023. PMID: 36672341 Free PMC article.
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Ascierto PA, et al. Among authors: schilling b. J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1. J Transl Med. 2015. PMID: 26619946 Free PMC article.
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Süsskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf D. Griewank KG, et al. Among authors: schilling b. Clin Cancer Res. 2013 Jun 15;19(12):3143-52. doi: 10.1158/1078-0432.CCR-13-0163. Epub 2013 Apr 30. Clin Cancer Res. 2013. PMID: 23633454
591 results